These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 24696094

  • 1. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F, Dorflinger E, Wettstein JG, Bausch A, Garibaldi G, Santarelli L.
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [Abstract] [Full Text] [Related]

  • 2. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.
    Bugarski-Kirola D, Wang A, Abi-Saab D, Blättler T.
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1024-36. PubMed ID: 24735806
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S.
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C, Banken L, Hahn M, Swearingen D, Nagel S, Martin-Facklam M.
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [Abstract] [Full Text] [Related]

  • 5. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
    Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR.
    Biol Psychiatry; 2017 Jul 01; 82(1):8-16. PubMed ID: 28117049
    [Abstract] [Full Text] [Related]

  • 6. A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.
    Hirayasu Y, Sato S, Takahashi H, Iida S, Shuto N, Yoshida S, Funatogawa T, Yamada T, Higuchi T.
    BMC Psychiatry; 2016 Mar 15; 16():66. PubMed ID: 26980460
    [Abstract] [Full Text] [Related]

  • 7. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH, Jansen WT, Schipper J, Szegedi A.
    J Clin Psychopharmacol; 2014 Apr 15; 34(2):190-8. PubMed ID: 24525661
    [Abstract] [Full Text] [Related]

  • 8. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.
    J Clin Psychiatry; 2012 Jun 15; 73(6):e728-34. PubMed ID: 22795211
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
    Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, Sun H, Marder S.
    Schizophr Res; 2017 Apr 15; 182():90-97. PubMed ID: 27789188
    [Abstract] [Full Text] [Related]

  • 10. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G, Lane HY, Yang P, Chong MY, Lange N.
    Biol Psychiatry; 2004 Mar 01; 55(5):452-6. PubMed ID: 15023571
    [Abstract] [Full Text] [Related]

  • 11. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V, Miodownik C, Gibel A, Sirota P, Bush I, Elliot H, Benatov R, Ritsner MS.
    J Clin Psychiatry; 2013 Dec 01; 74(12):1224-32. PubMed ID: 24434091
    [Abstract] [Full Text] [Related]

  • 12. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.
    J Clin Psychiatry; 2009 Oct 01; 70(10):1416-23. PubMed ID: 19906345
    [Abstract] [Full Text] [Related]

  • 13. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G.
    Biol Psychiatry; 2006 Sep 15; 60(6):645-9. PubMed ID: 16780811
    [Abstract] [Full Text] [Related]

  • 14. Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers.
    Hofmann C, Pizzagalli F, Boetsch C, Alberati D, Ereshefsky L, Jhee S, Patat A, Boutouyrie-Dumont B, Martin-Facklam M.
    Psychopharmacology (Berl); 2016 Jul 15; 233(13):2429-39. PubMed ID: 27178435
    [Abstract] [Full Text] [Related]

  • 15. Neurophysiological Effects of Bitopertin in Schizophrenia.
    Kantrowitz JT, Nolan KA, Epstein ML, Lehrfeld N, Shope C, Petkova E, Javitt DC.
    J Clin Psychopharmacol; 2017 Aug 15; 37(4):447-451. PubMed ID: 28590364
    [Abstract] [Full Text] [Related]

  • 16. Schizophrenia drug gets negative results for negative symptoms.
    Kingwell K.
    Nat Rev Drug Discov; 2014 Apr 15; 13(4):244-5. PubMed ID: 24687052
    [No Abstract] [Full Text] [Related]

  • 17. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
    Kantrowitz JT, Epstein ML, Lee M, Lehrfeld N, Nolan KA, Shope C, Petkova E, Silipo G, Javitt DC.
    Schizophr Res; 2018 Jan 15; 191():70-79. PubMed ID: 28318835
    [Abstract] [Full Text] [Related]

  • 18. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I.
    Clin Ther; 2010 Feb 15; 32(2):275-92. PubMed ID: 20206786
    [Abstract] [Full Text] [Related]

  • 19. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.
    Arch Gen Psychiatry; 2005 Nov 15; 62(11):1196-204. PubMed ID: 16275807
    [Abstract] [Full Text] [Related]

  • 20. Bitopertin: the good news and bad news.
    Goff DC.
    JAMA Psychiatry; 2014 Jun 15; 71(6):621-2. PubMed ID: 24696065
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.